office@csci-scrc.ca

main office

877-968-9449

toll-free

114 Cheyenne Way

Ottawa, On K2J 0E9

Benjamin Hibbert, MD, PhD, FRCPC

Councillor - University of Ottawa

Benjamin Hibbert, MD, PhD, FRCPC

Dr. Hibbert’s research program focuses on meta-research (studying principles and practices of scientific methods and publication), translational vascular biology and clinical research.

Most basic science studies cannot be reproduced which leads to wasted resources in duplication, follow-up studies and/or attempts at clinical translation. Our meta-research program has focused on improving reproducibility and enhancing translation of basic science by evaluating methodological rigor and the process(es) of research design, execution and dissemination. By understanding current practices and barriers to appropriate study design, we aim to improve the efficiency of the scientific enterprise with evidence based interventions at a system level.

Our translational research program focuses on the blood-vessel interface in the post-PCI (following stent insertion) artery with the goal of developing novel strategies to improve patient outcomes. In cardiovascular medicine the post-PCI lesion remains the highest risk of recurrent events – with between 5-10% of patients experiencing an event or needing re-intervention. Using primarily samples from patients, large animal models and ex vivo modeling of thrombosis and restenosis we aim to improve prognostication and identify and validate novel therapeutic targets to rapidly translate into clinical evaluation.

Finally, our group runs a large clinical research program including observational outcomes based research through randomized clinical trials. Complimenting clinical care, we have active research in critical care cardiology (cardiogenic shock, focused cardiac ultrasound), percutaneous coronary interventions (impact of medical regimens on bleeding outcomes, transradial access, non-invasive and invasive ischemia testing), and structural heart disease (mitraclip, novel devices for heart failure and/or valvular heart disease, left atrial appendage closure).